Vertex Pharmaceuticals (VRTX) and Zai Lab (ZLAB) said Friday they have signed a licensing deal to develop and commercialize povetacicept in mainland China, Hong Kong, Macau, Taiwan, and Singapore.
Zai Lab will oversee clinical trials, regulatory submissions, and marketing in the licensed territory, the companies said.
Vertex will receive an upfront payment, regulatory milestone payments, and tiered royalties on net sales of the drug, they added.
Vertex's Povetacicept is being studied for the treatment of1 Immunoglobulin A nephropathy and other B cell-mediated diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments